Author:
Singh Sheo B.,Odingo Joshua,Bailey Mai A.,Sunde Bjorn,Korkegian Aaron,O’Malley Theresa,Ovechkina Yulia,Ioerger Thomas R.,Sacchettini James C.,Young Katherine,Olsen David B.,Parish Tanya
Abstract
AbstractA set of ∼500 purified natural product compounds was screened for inhibition against the human pathogen Mycobacterium tuberculosis. A series of cyclic hexapeptides with anti-tubercular activity was identified. Five analogs from a set of sixteen closely related compounds were active, with minimum inhibitory concentrations ranging from 2.3-8.9 μM. Eleven structural analogs had no significant activity (MIC > 20 μM) demonstrating structure activity relationship. Sequencing of resistant mutant isolates failed to identify changes accounting for the resistance phenotype.
Publisher
Cold Spring Harbor Laboratory
Reference15 articles.
1. WHO. 2016. Global Tuberculosis Report. http://wwww hoint/tb/publications/global_report/en/.
2. Current challenges in drug discovery for tuberculosis;Expert Opin Drug Discov,2017
3. The future for early-stage tuberculosis drug discovery
4. Carroll P , Schreuder LJ , Muwanguzi-Karugaba J , Wiles S , Robertson BD , Ripoll J , Ward TH , Bancroft GJ , Schaible UE , Parish T. 2010. Sensitive Detection of Gene Expression in Mycobacteria under Replicating and Non-Replicating Conditions Using Optimized Far-Red Reporters. Plos One 5.
5. A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis